Study wrapper · #932
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
Abulehia A, Ayesh H, Ayesh O, et al. Endocrinology, diabetes & metabolism. 2026.
DOI: 10.1002/edm2.70187PubMed: 41787737
Editor's note
This network meta-analysis of fourteen randomized controlled trials places it high in the evidence hierarchy for comparing glucagon receptor agonists. Retatrutide was associated with the largest weight and HbA1c reductions but ranked lower on tolerability than mazdutide. The authors call for head-to-head trials to confirm the indirect comparisons.
Plain-language abstract
A network meta-analysis of randomized trials found retatrutide produced the greatest weight and HbA1c reductions among glucagon receptor agonists, though with comparatively lower tolerability.
Related coverage
Supported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
BMJ (Clinical research ed.)n=——2026
Weak / none
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Behavioural brain researchn=——2026
Supported
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
High blood pressure & cardiovascular preventionn=——2026